1. Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases
   Wei Peng et al, 2022, Aging and disease CrossRef
2. Advanced Glycation End Products (AGEs), Receptor for AGEs, Diabetes, and Bone: Review of the Literature
   Kamyar Asadipooya et al, 2019, Journal of the Endocrine Society CrossRef
3. Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes
   Savita Bansal et al, 2023, World Journal of Diabetes CrossRef
4. Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial
   Ehtasham Ahmad et al, 2021, Diabetes, Obesity and Metabolism CrossRef
5. P-selectin targeted RAGE-shRNA lipoplexes alleviate atherosclerosis-associated inflammation
   Cristina Ana Mocanu et al, 2021, Journal of Controlled Release CrossRef
6. Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro
   Jingquan Ji et al, 2022, Bioengineered CrossRef
7. Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin‐induced diabetic rats
   Umit Baylan et al, 2022, European Journal of Clinical Investigation CrossRef
8. RAGE/DIAPH1 and atherosclerosis through an evolving lens: Viewing the cell from the “Inside – Out”
   Ravichandran Ramasamy et al, 2024, Atherosclerosis CrossRef
9. RAGE and TLRs as Key Targets for Antiatherosclerotic Therapy
   Wioletta Olejarz et al, 2018, BioMed Research International CrossRef
10. Liraglutide, a glucagon-like peptide-1 receptor agonist, induces ADAM10-dependent ectodomain shedding of RAGE via AMPK activation in human aortic endothelial cells
    Chung Hee Baek et al, 2022, Life Sciences CrossRef
11. Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes
    Xianyu Zhang et al, 2024, BMC Musculoskeletal Disorders CrossRef
12. The role of RAGE in host pathology and crosstalk between RAGE and TLR4 in innate immune signal transduction pathways
    Daniel Prantner et al, 2020, The FASEB Journal CrossRef
13. Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs
    Richard Le et al, 2024, Journal of Clinical Medicine CrossRef
14. RAGE is a Potential Cause of Onset and Progression of Nonalcoholic Fatty Liver Disease
    Kamyar Asadipooya et al, 2019, International Journal of Endocrinology CrossRef
15. HPP and SGQR peptides from silkworm pupae protein hydrolysates regulated biosynthesis of cholesterol in HepG2 cell line
    Suling Sun et al, 2021, Journal of Functional Foods CrossRef